16 Updates, Four New Recommendations Issued for Management of Pediatric VTE

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, May 30, 2025 -- In clinical guidelines issued by the American Society of Hematology and the International Society on Thrombosis and Haemostasis, and published online May 27 in Blood Advances, new and updated recommendations are presented for the treatment of pediatric venous thromboembolism (VTE).

Paul Monagle, M.D., M.B.B.S., from the University of Melbourne in Australia, and colleagues developed evidence-based guidelines to support patients, clinicians, and other health care professionals in decisions regarding management of pediatric patients with VTE.

The authors updated 16 recommendations and added four new recommendations. These include suggested use of anticoagulation rather than no anticoagulation for pediatric patients with symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE) (conditional recommendation). Use of anticoagulation or no anticoagulation is suggested for pediatric patients with clinically unsuspected (asymptomatic) DVT or PE (conditional recommendation). Six weeks of anticoagulation is suggested rather than three months for select pediatric patients with provoked VTE (conditional recommendation). Anticoagulation is suggested for six to 12 months rather than indefinitely for pediatric patients with unprovoked DVT or PE (conditional recommendation). Direct oral anticoagulants (rivaroxaban/dabigatran) are suggested over standard of care anticoagulants (low molecular weight heparin, unfractionated heparin, vitamin K antagonist, or fondaparinux) for pediatric patients with VTE (conditional recommendation). Use of either rivaroxaban or dabigatran is suggested for pediatric patients with VTE, with individual populations or jurisdictional availability leading clinicians to choose one over the other.

"The care of children is important, and parents should know that there is a body of evidence that supports their child's treatment options," Monagle said in a statement.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-05-31 00:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords